Onconetix granted Nasdaq continued listing; completes reverse stock split to meet bid price rule

Onconetix, Inc.

Nasdaq Hearings Panel granted continued listing on June 11, 2025, subject to compliance by June 30, 2025.
Company met periodic filing rule by filing Q1 10-Q on June 12, 2025.
Completed 1-for-85 reverse stock split on June 13, 2025 to address bid price requirement.
Expects to demonstrate compliance with bid price rule by close of business June 27, 2025.
Hearing held May 27, 2025; company's request for continued listing was granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.